Anti-CCN4/ WISP1/ WISP1-OT1 functional antibody
Anti-CCN4/ WISP1/ WISP1-OT1 functional antibody for cell culture, ELISA & in-vivo assay
Go to WISP1/CCN4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T71859-Ab-1/ GM-Tg-hg-T71859-Ab-2 | Anti-Human WISP1/CCN4 monoclonal antibody | Human |
GM-Tg-rg-T71859-Ab-1/ GM-Tg-rg-T71859-Ab-2 | Anti-Rat WISP1/CCN4 monoclonal antibody | Rat |
GM-Tg-mg-T71859-Ab-1/ GM-Tg-mg-T71859-Ab-2 | Anti-Mouse WISP1/CCN4 monoclonal antibody | Mouse |
GM-Tg-cynog-T71859-Ab-1/ GM-Tg-cynog-T71859-Ab-2 | Anti-Cynomolgus/ Rhesus macaque WISP1/CCN4 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T71859-Ab-1/ GM-Tg-felg-T71859-Ab-2 | Anti-Feline WISP1/CCN4 monoclonal antibody | Feline |
GM-Tg-cang-T71859-Ab-1/ GM-Tg-cang-T71859-Ab-2 | Anti-Canine WISP1/CCN4 monoclonal antibody | Canine |
GM-Tg-bovg-T71859-Ab-1/ GM-Tg-bovg-T71859-Ab-2 | Anti-Bovine WISP1/CCN4 monoclonal antibody | Bovine |
GM-Tg-equg-T71859-Ab-1/ GM-Tg-equg-T71859-Ab-2 | Anti-Equine WISP1/CCN4 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T71859-Ab-1/ GM-Tg-hg-T71859-Ab-2; GM-Tg-rg-T71859-Ab-1/ GM-Tg-rg-T71859-Ab-2; GM-Tg-mg-T71859-Ab-1/ GM-Tg-mg-T71859-Ab-2; GM-Tg-cynog-T71859-Ab-1/ GM-Tg-cynog-T71859-Ab-2; GM-Tg-felg-T71859-Ab-1/ GM-Tg-felg-T71859-Ab-2; GM-Tg-cang-T71859-Ab-1/ GM-Tg-cang-T71859-Ab-2; GM-Tg-bovg-T71859-Ab-1/ GM-Tg-bovg-T71859-Ab-2; GM-Tg-equg-T71859-Ab-1/ GM-Tg-equg-T71859-Ab-2 |
Products Name | Anti-WISP1/CCN4 monoclonal antibody |
Format | mab |
Target Name | WISP1 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-WISP1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T71859-Ag-1 | Recombinant multi-species CCN4/ WISP1/ WISP1-OT1 protein |
Cytokine | GM-Tg-g-T71859-Ag-1 | WNT1 inducible signaling pathway protein 1 (WISP1) protein |
ORF Viral Vector | vGMLP003599 | human WISP1 Lentivirus particle |
ORF Viral Vector | pGMLP003599 | human WISP1 Lentivirus plasmid |
ORF Viral Vector | pGMLV000096 | mouse Wisp1 Lentivirus plasmid |
ORF Viral Vector | vGMLV000096 | mouse Wisp1 Lentivirus particle |
Target information
Target ID | GM-T71859 |
Target Name | WISP1 |
Gene ID | 8840,22402,65154,697624,482048,101093993,539163,100068971 |
Gene Symbol and Synonyms | CCN4,Elm1,WISP1,WISP1-OT1,WISP1-UT1,WISP1c,WISP1i,WISP1tc |
Uniprot Accession | O95388,Q99PP0 |
Uniprot Entry Name | CCN4_HUMAN,CCN4_RAT |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Therapeutics Target, Cytokine Target |
Disease | Breast Cancer |
Gene Ensembl | ENSG00000104415 |
Target Classification | N/A |
The target: WISP1, gene name: CCN4, also named as WISP1, WISP1-OT1, WISP1-UT1, WISP1c, WISP1i, WISP1tc. This gene encodes a member of the WNT1 inducible signaling pathway (WISP) protein subfamily, which belongs to the connective tissue growth factor (CTGF) family. WNT1 is a member of a family of cysteine-rich, glycosylated signaling proteins that mediate diverse developmental processes. The CTGF family members are characterized by four conserved cysteine-rich domains: insulin-like growth factor-binding domain, von Willebrand factor type C module, thrombospondin domain and C-terminal cystine knot-like domain. This gene may be downstream in the WNT1 signaling pathway that is relevant to malignant transformation. It is expressed at a high level in fibroblast cells, and overexpressed in colon tumors. The encoded protein binds to decorin and biglycan, two members of a family of small leucine-rich proteoglycans present in the extracellular matrix of connective tissue, and possibly prevents the inhibitory activity of decorin and biglycan in tumor cell proliferation. It also attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. It is 83% identical to the mouse protein at the amino acid level. Multiple alternatively spliced transcript variants have been identified. [provided by RefSeq, Mar 2011].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.